Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

Clinical trial NCT03620955 · UNKNOWN

Trial details

NCT number: NCT03620955
Sponsor: Nanfang Hospital, Southern Medical University
Status: UNKNOWN
Study type: OBSERVATIONAL

Risk-directed Therapy Cytogenetic Abnormality Molecular Abnormality MRD

Start date: 2018-08-10
Primary completion: 2020-12-01
Enrollment: 1000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.